2021 기타 The knowledge and attitude of patients diafnosed with epithelial ovarian cancer towards genetic testing: International journal of environmental research and public health. :~ (2.849)
2020 SCI-E Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial: LANCET ONCOLOGY. 21(12):1653~1660 (33.752)
2020 SCI-E Glycolytic phenotypes in an evaluation of ovarian carcinoma based on carcinogenesis and BRCA mutation.: EUROPEAN JOURNAL OF RADIOLOGY. 133:109391~ (2.687)
2020 SCI-E Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: YONSEI MEDICAL JOURNAL. 61(11):935~941 (1.914)
2020 SCI-E A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer: BRITISH JOURNAL OF CANCER. Online:Published (5.791)
2020 SCI-E The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis: JOURNAL OF OVARIAN RESEARCH. 13(1):97~ (2.989)
2020 SCI-E Uptake of Family-specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2mutation: CANCER RESEARCH AND TREATMENT. Online:Published (3.761)
2020 SCI-E Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 30(6):764~771 (2.095)
2020 SCI-E Comprehensive geriatric assessment is correlated to overall survival among gynaecologic oncology patients: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 50(3):276~281 (1.914)
2020 SCI-E Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study: JOURNAL OF GYNECOLOGIC ONCOLOGY. 31(2):e15~ (3.304)
2020 SCI-E Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. 52(2):396~405 (3.761)
2019 Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study: . : ()
2019 SCI Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer: THE NEW ENGLAND JOURNAL OF MEDICINE. 20:1929~1939 (70.67)
2019 SCI-E A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D: JOURNAL OF GYNECOLOGIC ONCOLOGY. Online:Published (2.914)
2019 SCI Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. Online:Published (3.363)
2019 SCI-E Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: THE LANCET ONCOLOGY. 20(6):862~876 (35.386)2021 기타 The knowledge and attitude of patients diafnosed with epithelial ovarian cancer towards genetic testing: International journal of environmental research and public health. :~ (2.849)
2020 SCI-E Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial: LANCET ONCOLOGY. 21(12):1653~1660 (33.752)
2020 SCI-E Glycolytic phenotypes in an evaluation of ovarian carcinoma based on carcinogenesis and BRCA mutation.: EUROPEAN JOURNAL OF RADIOLOGY. 133:109391~ (2.687)
2020 SCI-E Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: YONSEI MEDICAL JOURNAL. 61(11):935~941 (1.914)
2020 SCI-E A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer: BRITISH JOURNAL OF CANCER. Online:Published (5.791)
2020 SCI-E The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis: JOURNAL OF OVARIAN RESEARCH. 13(1):97~ (2.989)
2020 SCI-E Uptake of Family-specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2mutation: CANCER RESEARCH AND TREATMENT. Online:Published (3.761)
2020 SCI-E Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 30(6):764~771 (2.095)
2020 SCI-E Comprehensive geriatric assessment is correlated to overall survival among gynaecologic oncology patients: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 50(3):276~281 (1.914)
2020 SCI-E Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study: JOURNAL OF GYNECOLOGIC ONCOLOGY. 31(2):e15~ (3.304)
2020 SCI-E Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. 52(2):396~405 (3.761)
2019 Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study: . : ()
2019 SCI Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer: THE NEW ENGLAND JOURNAL OF MEDICINE. 20:1929~1939 (70.67)
2019 SCI-E A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D: JOURNAL OF GYNECOLOGIC ONCOLOGY. Online:Published (2.914)
2019 SCI Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: CANCER RESEARCH AND TREATMENT. Online:Published (3.363)
2019 SCI-E Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: THE LANCET ONCOLOGY. 20(6):862~876 (35.386)
2019 SCI-E Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. Online:Published (2.183)
2019 SCI-E Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial: THE LANCET ONCOLOGY. Online:Published (35.386)
2019 SCI-E Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study: JOURNAL OF GYNECOLOGIC ONCOLOGY. 30(3):e44~e44 (2.914)
2019 SCI-E Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708): BMC CANCER. 19(1):341~341 (2.933)
2019 SCI-E Delayed IL-21 treatment preferentially expands peptide-specific CD8+ T cells by reducing bystander activation of T cells: IMMUNOTHERAPY. 11(6):497~513 (3.028)
2019 SCI Suprarenal lymph node dissection by the Kocher maneuver in the surgical management of ovarian cancer: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 29(3):647~648 (1.746)
2019 SCI Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041): GYNECOLOGIC ONCOLOGY. 152(1):61~67 (4.54)
2019 SCI-E Peritoneal cancer index in ovarian cancer: JOURNAL OF GYNECOLOGIC ONCOLOGY. 30(1):e14~e14 (2.914)
2019 SCI-E Functional loss in daily activity in ovarian cancer patients undergoing chemotherapy: Archives of Gynecology and Obstetrics. Online:Published (2.236)
2018 SCI-E Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: CANCER RESEARCH AND TREATMENT. 51(1):112~118 (3.23)
2018 SCI-E Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers: CANCER RESEARCH AND TREATMENT. 51(1):280~288 (3.23)
2018 SCI Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy: International journal of gynecological cancer. 28(9):1676~1682 (2.192)
2018 SCI Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial: Gynecologic oncology. 151(1):39~45 (4.54)
2018 SCI-E Comparison of gynecologic cancer risk factors, incidence and mortality trends between South Korea and Israel, 1999-2013: Japanese journal of clinical oncology. 48(10):884~891 (2.37)
2018 SCI Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer: International journal of gynecological cancer. 28(8):1631~1638 (2.192)
2018 SCI-E Changes in ovarian cancer survival during the 20 years before the era of targeted therapy: BMC Cancer. 18(1):601~601 (3.288)
2018 SCI-E Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons: World journal of surgical oncology. 16(1):92~92 (1.792)
2018 SCI Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae: Journal of cancer research and clinical oncology. 144(5):845~854 (3.282)